Cargando…
Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
BACKGROUND/AIMS: Metabolic dysfunction associated fatty liver disease (MAFLD) has recently been introduced to compensate for the conventional concept of nonalcoholic fatty liver disease (NAFLD). We explored whether fibrotic burden determines the risk of atherosclerotic cardiovascular disease (ASCVD)...
Autores principales: | Han, Eugene, Lee, Yong-ho, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Kim, Seung Up |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474484/ https://www.ncbi.nlm.nih.gov/pubmed/35321955 http://dx.doi.org/10.5009/gnl210290 |
Ejemplares similares
-
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
por: Kim, Yuna, et al.
Publicado: (2022) -
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
por: Chun, Ho Soo, et al.
Publicado: (2021) -
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
por: Lim, Tae Seop, et al.
Publicado: (2023) -
Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level
por: Jeon, Mi Young, et al.
Publicado: (2018) -
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
por: Chang, Jin Won, et al.
Publicado: (2021)